Venatorx Pharmaceuticals’ second development-stage product in clinical development is VNRX-7145, an orally bioavailable beta-lactamase inhibitor (BLI) that in a fixed combination with the third generation orally bioavailable cephalosporin, ceftibuten, has the potential to rescue activity of the partner antibiotic against extended spectrum beta-lactamases (ESBLs) and key carbapenem-resistant Enterobacteriaceae, including those expressing Klebsiella pneumoniae carbapenemase (KPC) and Oxacillinase (OXA) carbapenemases.
This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C.
|You are using a browser that is not supported. Please consider changing your browser|